Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Bone Marrow Transplant. 2019 Jan 22;54(8):1337–1345. doi: 10.1038/s41409-019-0438-z

Table 2:

Second hematopoietic transplants

HCT#1 HCT #2
Original
Transplant
Indication		 Regimen
(Gy)		 Donor Time to
Relapse
(days)		 Phase of
Disease at
2nd HCT		 Regimen Donor Alive Cause
of death
ALL
CR1 CYTBI 12.0 MSD 91 CR M-CH MSD N Relapse
CR1 MRD(−) TBICY 12.0 URD 96 CR MRD(−) NM URD N Relapse
CR1 MRD(−) CYTBI 13.2 MSD 216 CR MRD(−) RIC CB N Relapse
CR1 MRD(−) TBICY 13.2 MSD 309 CR MRD(+) RIC URD N Relapse
CR1 MRD(−) TBICY 13.2 MSD 323 CR MRD(+) RIC CB N Relapse
CR1 MRD(+) TBICY 13.2 MSD 191 CR MRD(+) RIC URD N TRM
CR1 MRD(+) TBICY 13.2 URD 343 CR MRD (−) NM URD Y*
CR1 MRD(+) CYTBI 14.4 URD 348 PD M-CH URD N TRM
CR2 CYTBI 15.75 MSD 239 PD M-CH MSD N Relapse
CR2 CYTBI 15.75 MSD 315 PD M-CH MSD N TRM
CR2 CYTBI 15.75 MSD 361 PD M-CH MSD N Relapse
CR2 TBICY 13.2 MSD 1009 CR MRD(−) RIC CB Y
CR2 MRD(−) TBICY 13.2 URD 1319 CR MRD(−) NM URD N Relapse
CR2 MRD(+) TBICY 13.2 MSD 80 CR MRD(+) RIC Haplo N Relapse
CR2 MRD(+) TBICY 13.2 URD 96 PD M-CH URD N TRM
CR2 MRD(+) TBICY 13.2 MSD 395 CR MRD(−) RIC URD N TRM
CR2 MRD(+) CYTBI 12.0 URD 439 CR MRD(−) NM URD N Relapse
CR3 TBICY13.2 URD 517 CR MRD(+) RIC CB Y
CR3 TTCYTBI 12.0 MSD 2756 CR MRD(+) M-CH MSD N TRM
CR3 MRD(+) TBICY14.4 URD 1230 UN RIC URD N Relapse
PrimRef CYTBI 15.75 MSD 178 PD M-CH MSD N Relapse
AML
CR1 MRD(−) BUCY MSD 75 CR MRD(+) M-TBI URD N TRM
CR1 BUCY Haplo 189 PD M-TBI Haplo N TRM
CR1 BUCYTBI MSD 307 PD M-TBI MSD N TRM
CR1 BUCY MSD 691 CR M-TBI MSD Y
CR1 MRD(−) CYTBI 14.4 Haplo 648 PD M-CH Haplo N Relapse
CR1 MRD(−) BUCY MSD 2493 CR MRD(−) M-TBI URD N TRM
CR1 MRD(+) FluCYTBI13.2 CB 219 CR MRD(−) RIC CB N TRM
CR1 MRD(+) BUCY MSD 231 CR MRD(−) M-TBI MSD N TRM
CR1 MRD(+) BUCY Haplo 257 CR MRD(−) M-TBI URD N TRM
CR1 MRD(+) BUCY MSD 320 CR MRD(−) M-TBI MSD Y
CR1 MRD(+) CYTBI 14.4 URD 333 CR M-CH MSD N Relapse
CR1 MRD(+) 131IBUCY MSD 408 CR M-TBI MSD N Relapse
CR2 BUCY MSD 2215 CR M-TBI MSD N TRM
PrimRef TBICY 13.2 URD 78 CR MRD- RIC CB Y
PrimRef CYTBI 14.4 URD 144 CR M-CH URD Y
PrimRef TBICY 13.2 MSD 214 CR MRD- NM MSD N Relapse
PrimRef BUCYTBI 12 MSD 229 PD M-CH MSD N Relapse
PrimRef CYTBI 14.4 Hap 391 PD M-CH Hap N Relapse
PrimRef CYTBI 14.4 URD 416 CR MRD- M-CH URD N TRM
PrimRef CYTBI 15.75 Hap 452 PD M-CH Hap N TRM
REL BUCY MSD 55 PD M-TBI MSD N Relapse
REL TBICY 13.2 HAP 75 PD M-CH HAP N Relapse
REL TBICY 13.2 URD 126 CR MRD+ NM URD N* Trauma
MDS/MPS
MDS EB CYTBI 14.4 MSD 82 PD RIC HAP Y
MDS EB BUCY URD 128 CR MRD- M-TBI URD N Relapse
MDS EB BUCY MSD 132 PD M-TBI MSD N Relapse
MDS EB BUCY MSD 132 PD M-TBI MSD N TRM
MDS EB BUCY URD 247 PD M-TBI URD Y
MDScEB CYTBI 12 MSD 961 PD M-CH MSD N Relapse
MPS EB FluCY 13.2 CB 307 PD RIC URD N Relapse

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BU, busulfan; CB, cord blood; CH, chemotherapy; CR, complete remission; CY, cyclophosphamide; D/C IS, discontinue immune suppression; DLI, donor lymphocyte infusion; EB, excess blasts; FLU, fludarabine; HAP, HLA-haploidentical donor; HCT, hematopoietic cell transplant; 131I, iodine-131; MDS, myelodysplastic syndrome; M-CH, chemotherapy-based myeloablative conditioning; MPS, myeoproliferative syndrome; MRD (−), no minimal residual disease; MRD (+), minimal residual disease; MSD, matched sibling donor; M-TBI, TBI- based myeloablative conditioning; N, no; NM, nonmeyloablative conditioning; PD, disease not in remission; PrimRef, primary refractory; REL, refractory relapse; RIC, reduced intensity conditioning; Rx, treatment for relapse; SOR, sorafenib; TBI, total body irradiation; TKI, tyrosine kinase inhibitor; TT, thiotepa; UN, unknown; URD, unrelated donor; Y, yes.

*

alive after 3rd transplant

**

died in remission from car accident